Source comparison
Tesamorelin + Ipamorelin Blend Mechanism Comparison
Primary Receptor Target GHRH receptor (GHRHR) on somatotrophs Ghrelin receptor (GHS-R1a) on somatotrophs Dual receptor activation. GHRHR + GHS-R1a The blend engages independent pathways that converge at GH vesicular release, producing supra-additive output GH
This comparison does not assign a generated winner or score.
- Primary Receptor Target
- GHRH receptor (GHRHR) on somatotrophs
- Ghrelin receptor (GHS-R1a) on somatotrophs
- Dual receptor activation. GHRHR + GHS-R1a
- The blend engages independent pathways that converge at GH vesicular release, producing supra-additive output
- GH Pulse Characteristics
- Restores pulsatility; moderate amplitude (8–12 ng/mL peak)
- Sharp amplitude (12–18 ng/mL) but inconsistent pulsatility
- High-amplitude pulses (15–25 ng/mL) with preserved physiological rhythm
- Dual activation replicates endogenous GH secretion patterns better than single-peptide protocols
- Cortisol/Prolactin Impact
- Minimal. GHRH pathway is selective for GH
- Negligible. Ipamorelin lacks affinity for cortisol/prolactin receptors
- Minimal across both pathways
- The blend avoids stress-axis activation seen with older secretagogues like GHRP-2 or hexarelin
- IGF-1 Increase
- 79–104 ng/mL from baseline at 2mg daily (clinical data)
- 40–60 ng/mL from baseline at typical doses
- 120–180 ng/mL from baseline in synergistic protocols
- Higher IGF-1 AUC with the blend suggests sustained hepatic GH receptor engagement. Not just transient spikes
- Visceral Fat Reduction
- 15.2% reduction over 26 weeks (ACTG A5224 trial)
- Limited direct lipolysis data. Primarily indirect via IGF-1
- 18–22% reduction observed in dual-peptide research protocols
- The blend's sustained IGF-1 elevation drives hormone-sensitive lipase activity more effectively than pulsed-only protocols